Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Aggarwal and Gandara on Incorporating Liquid Biopsies Into the Lung Cancer Armamentarium

November 9th 2020

In our exclusive interview, Dr. Aggarwal and Dr. Gandara discuss the evolution of liquid biopsy in lung cancer, explain the clinical implications of recent liquid biopsy approvals, and forecast the future of liquid biopsy in the field.

ctDNA Shows Promise as a Potential Biomarker for MRD in Locally Advanced NSCLC

November 9th 2020

Maximilian Diehn, MD, PhD, discusses how the use of circulating tumor DNA to analyze minimal residual disease status in patients with lung cancer and other solid tumors is a rapidly developing field with the potential to further personalize treatment decisions about adjuvant therapy.

Halmos Highlights Lessons Learned From the COVID-19 Crisis in Lung Cancer

November 9th 2020

The oncology community has risen up as a unified front in the battle against coronavirus disease 2019, launching pivotal research efforts to better understand the enemy and collecting data to develop effective therapeutics to fill the treatment arsenal.

TMB Shows Potential as Immunotherapy Biomarker in Lung Cancer, But Challenges Remain

November 7th 2020

Tumor mutational burden has been associated with response to immunotherapy in patients with lung cancer, but there have been various criticisms regarding the validity and routine use of this as a biomarker.

Management of Small Cell Lung Cancer Moves Forward With Immunotherapy

November 7th 2020

Frontline chemoimmunotherapy trials represent a critical milestone in extensive-stage small cell lung cancer, but one that requires better understanding of the methods that can be used to broaden the patient population in whom durable benefit is currently concentrated.

Efforts to Target Actionable Alterations in Lung Cancer Abound, Emphasizing Need for Testing

November 7th 2020

Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discusses the actionable mutations that have been identified in the lung cancer space, the agents that have been developed to target them, and the importance of genetic testing to provide personalized care.

Dr. Rohs on the Importance of Genetic Testing in NSCLC

November 7th 2020

Nicholas C. Rohs, MD, discusses the importance of genetic testing in non–small cell lung cancer.

Dr. Rizk on the Evolution of Surgery in Lung Cancer

November 7th 2020

Nabil P. Rizk, MD, MS, MPH, discusses the evolving role of surgery in lung cancer.

Neratinib Shows Early Activity in EGFR Exon 18–Mutated, Metastatic NSCLC

November 6th 2020

Neratinib showcased early activity when used in patients with metastatic non–small cell lung cancer who harbor EGFR exon 18 mutations.

Nivolumab/Ipilimumab Plus Chemo Approved in Europe for Frontline Metastatic NSCLC

November 6th 2020

The European Commission has approved the combination of nivolumab plus ipilimumab with 2 cycles of platinum-based chemotherapy for the up-front treatment of adult patients with metastatic non–small cell lung cancer without a sensitizing EGFR mutation or an ALK translocation.

Dr. Patel on the Role of Immunotherapy Combinations in Lung Cancer

November 2nd 2020

Sandip P. Patel, MD, discusses the role of immunotherapy combinations in lung cancer.

ADAURA Generates Excitement for Targeted Therapy in Adjuvant EGFR+ NSCLC

November 2nd 2020

Balazs Halmos, MD, MS, highlights the significance of the ADAURA trial in EGFR-positive NSCLC, questions raised by these data, and other efforts being made in the adjuvant setting.

Research Efforts Strive to Overcome Osimertinib Resistance in EGFR+ Lung Cancer

November 2nd 2020

Helena A. Yu, MD, discusses novel non–small cell lung cancer combinations and biomarkers that are under investigation in order to overcome osimertinib resistance

FDA Approves First Companion Diagnostic for Expanded EGFR TKIs in NSCLC

October 30th 2020

The FDA has approved the cobas EGFR Mutation Test v2 as a companion diagnostic for EGFR TKIs in the treatment of patients with EGFR-mutated non–small cell lung cancer.

Chemoimmunotherapy Combos “Game-Changing” in Frontline Metastatic NSCLC

October 30th 2020

Nicholas Rohs, MD, discusses the progress made with chemoimmunotherapy combinations in frontline non–small cell lung cancer, future research directions, and emerging approaches that seek to propel progress in this disease.

Dr. Spira on the Rationale of the CHRYSALIS Trial in EGFR-Mutant NSCLC

October 29th 2020

Alexander Spira, MD, PhD, FACP, discusses the rationale of the phase 1 CHRYSALIS trial with amivantamab plus lazertinib in EGFR-mutant non–small cell lung cancer.

Raez on the Rise of Liquid Biopsy in Lung Cancer

October 29th 2020

In our exclusive interview, Dr. Raez provides insight into the advantages and disadvantages of liquid biopsy relative to tissue biopsy and forecasts the utility of liquid biopsy within the field of lung cancer as more of these assays become available.

FDA Grants Priority Review to Cemiplimab for Advanced NSCLC With High PD-L1 Expression

October 29th 2020

The FDA has granted a priority review designation to a supplemental biologics license application for cemiplimab-rwlc for the frontline treatment of patients with locally advanced or metastatic non–small cell lung cancer with a PD-L1 expression of 50% or greater.

Martins Makes Sense of the Complicated Frontline NSCLC Treatment Landscape

October 29th 2020

Renato G. Martins, MD, discusses the many up-front approaches that have emerged in NSCLC, remaining questions to address with future efforts, and novel combinations under exploration.

Dr. Levy on the Mechanism of Action of Telaglenastat in NSCLC

October 28th 2020

Benjamin P. Levy, MD, discusses the mechanism of action of telaglenastat in non–small cell lung cancer.